Elutia Inc (ELUT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.82-2.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Maintain gross margin above 80%: 59.6% vs 80% target.
Elutia aims to keep gross margins above 80%. Operating losses have improved from negative $9.9 million to negative $6.3 million. The company is working to increase revenue beyond $3.3 million in 2025. These steps show progress toward profitability.
Revenue dropped from $6.3 million to $3.1 million recently. Operating losses remain negative and large. The company faces listing risks and market challenges. Growth and profit improvements may stall or reverse.
The market expects about 12% revenue decline next year and prices the stock roughly 10% below our valuation range. Our view differs by focusing on potential margin and income improvements despite revenue pressure.
Breaks if: gross margin falls below 75% in FY26
Implement manufacturing automation and scale production to support gross margins exceeding 80%.
Stated as a priority in 2 of last 3 quarters. Adjusted gross margin improved from 66.5% in 2026-Q1 to 70.7% in 2026-Q2, below the target of over 80% at scale. Manufacturing automation is installed and operational, supporting the target. The trajectory shows progress but the 80% margin target is not yet achieved.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, given its focus on advancing a new product and navigating a volatile management environment. The current thesis state is weakened due to recent earnings misses and declining revenue.
The market appears to price in a low valuation compared to peers, but there is an expectations gap indicating that investors may not fully believe in the company's recovery potential. The current valuation reflects a cheap position, yet the fundamentals suggest a need for improvement.
Fundamentals are likely to remain weak in the near term, as the company has reported a decline in revenue and faces challenges in achieving its gross margin targets. Management's focus on FDA clearance and commercial launch is on track, but overall financial performance has been stagnant.
The long-term thesis hinges on the company's ability to advance its product pipeline and improve financial performance. Key scenarios include the impact of sector momentum from larger healthcare companies and potential guidance cuts that could negatively affect investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance fell from the robust half to the weak half of its sector. This change indicates a decline in the reasons to own the company. However, securing $26 million in capital supports the FDA clearance and commercial launch of NXT-41x.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Completed installation and operational qualification of automated drug-coating system supporting gross margin targets above 80%.”
“New automated manufacturing process installed, supporting gross margin target of more than 80% at scale.”
Breaks if: operating loss worsens beyond -$7 million next year
Reduce operating losses through expense management and revenue growth.
Stated as a priority in 3 of last 3 quarters. Operating loss modestly improved from $8.4 million in 2025-Q2 to $8.0 million in 2026-Q2. Operating expenses decreased slightly but net loss remains significant. The trajectory shows limited progress in improving operating income.
“Loss from operations was $8.0 million, compared to $8.4 million in prior year.”
“Loss from continuing operations was $7.9 million, compared to $1.9 million prior year.”
“Operating income was negative $6.6 million.”
Breaks if: revenue falls below $3 million next year
Grow net sales by expanding product adoption and market penetration.
Stated as a priority in 3 of last 3 quarters. Revenue declined from $3.3 million in 2025-Q4 to $2.4 million in 2026-Q2, impacted by divestiture and production disruptions. Surgeon interest is strong and validated by surveys, but revenue growth has not yet materialized. The trajectory is currently stagnant with challenges to revenue growth.
“Surgeon interest in NXT-41x has exceeded our expectations; 96% interested in adopting.”
“Chief Commercial Officer confirms significant unmet need and market opportunity.”
“NXT-41x is designed for the $1.5 billion plastic and reconstructive surgery market.”
In the next 1 to 3 years, ELUT's outlook is uncertain, with significant risks and challenges ahead. Not investment advice.